- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00033475
Reduced Immunosuppressive Therapy With or Without Donor White Blood Cells in Treating Patients With Lymphoproliferative Disease After Organ Transplantation
Cytotoxic T Cell Therapy for Post Transplant Lymphoproliferative Disease: Randomized Controlled Trial in Transplant Recipients
RATIONALE: Some types of lymphoproliferative disease are associated with Epstein-Barr virus. Combining reduced immunosuppressive therapy with donor white blood cells that have been treated in the laboratory to kill cells infected with Epstein-Barr virus may be an effective treatment for lymphoproliferative disease.
PURPOSE: Randomized phase III trial to compare the effectiveness of reducing immunosuppressive therapy with or without donor white blood cells in treating patients who have Epstein-Barr virus-associated lymphoproliferative disease after organ transplantation.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OBJECTIVES:
- Determine the efficacy of treatment with partially HLA-matched allogeneic cytotoxic T cells and reduction of immunosuppression, in terms of survival rate and time to remission in patients with Epstein-Barr virus-associated B-cell lymphoproliferative disease after solid organ transplantation.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to transplanted organ type and transplant center. Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients undergo sliding-scale reduction of immunosuppressive drugs from 1 of 5 regimens at physician's discretion. Patients then receive partially HLA-matched allogeneic cytotoxic T cells IV over 5 minutes once weekly for a total of 4 weeks.
- Arm II: Patients undergo reduction of immunosuppression as in arm I alone. Patients are followed monthly for 6 months and then every 3 months for 2 years.
PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
England
-
Birmingham, England, United Kingdom, B4 6NH
- Birmingham Children's Hospital
-
Cambridge, England, United Kingdom, CB3 8RE
- Papworth Hospital
-
London, England, United Kingdom, SE5 8RX
- King's College Hospital
-
London, England, United Kingdom, NW3 2PF
- Royal Free and University College Medical School
-
Manchester, England, United Kingdom, M23 9LJ
- Wythenshawe Hospital
-
Manchester, England, United Kingdom, M27 4HA
- Central Manchester and Manchester Children's University Hospitals NHS Trust
-
Sheffield, England, United Kingdom, S5 7AU
- Northern General Hospital
-
Sutton, England, United Kingdom, SM2 5NG
- Institute of Cancer Research - UK
-
-
Scotland
-
Edinburgh, Scotland, United Kingdom, EH16 4SA
- Royal Infirmary of Edinburgh at Little France
-
Edinburgh, Scotland, United Kingdom, EH8 1QH
- University of Edinburgh
-
Edinburgh, Scotland, United Kingdom, EH9 1QH
- University of Edinburgh Laboratory for Clinical and Molecular Virology
-
Glasgow, Scotland, United Kingdom, G4 0SF
- Royal Infirmary - Castle
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
Diagnosis of post-transplant lymphoproliferative disease (PTLD) after solid organ (heart, heart/lung, liver, liver/gut, pancreas, or kidney) transplantation
- Epstein-Barr virus-positive tumor
- Newly diagnosed disease
- Measurable disease by clinical methods or radiography
- Must have partially matched donor cytotoxic T cells (CTL) available
- No known panel reactivity to any of the HLA types of CTL available for therapy
PATIENT CHARACTERISTICS:
Age:
- Any age
Performance status:
- Karnofsky 20-100%
Life expectancy:
- Not specified
Hematopoietic:
- Not specified
Hepatic:
- Not specified
Renal:
- Not specified
Other:
- Not pregnant
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- Not specified
Chemotherapy:
- Not specified
Endocrine therapy:
- Not specified
Radiotherapy:
- Not specified
Surgery:
- Not specified
Other:
- No prior therapy for PTLD
- No concurrent antiviral drugs (e.g., acyclovir or ganciclovir) for PTLD
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Stable disease
|
Complete response
|
Survival at 2 years
|
Partial response
|
Progressive disease
|
Time to complete remission
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Dorothy H. Crawford, MD, University of Edinburgh
Study record dates
Study Major Dates
Study Start
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CDR0000069288
- CRUK-EBV-CTL
- LCMV-CTL
- EU-20057
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoproliferative Disorder
-
Children's Oncology GroupNational Cancer Institute (NCI)Active, not recruitingEBV-Related Post-Transplant Lymphoproliferative Disorder | Monomorphic Post-Transplant Lymphoproliferative Disorder | Polymorphic Post-Transplant Lymphoproliferative Disorder | Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder | Recurrent Polymorphic Post-Transplant Lymphoproliferative... and other conditionsUnited States
-
Timothy VoorheesRecruitingPolymorphic Post-Transplant Lymphoproliferative Disorder | Monomorphic B-Cell Post-Transplant Lymphoproliferative DisorderUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI)TerminatedLymphoproliferative DisorderUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedRecurrent Lymphoproliferative Disorder | Refractory Lymphoproliferative DisorderUnited States
-
Charite University, Berlin, GermanyTerminatedPost-transplantation Lymphoproliferative DisorderAustralia, France, Germany, Sweden
-
Masonic Cancer Center, University of MinnesotaMillennium Pharmaceuticals, Inc.TerminatedLymphoproliferative DisorderUnited States
-
Diako Ev. Diakonie-Krankenhaus gemeinnützige GmbHCompletedPosttransplant Lymphoproliferative DisorderGermany
-
Invivoscribe, Inc.RecruitingB-Cell Lymphoproliferative DisorderUnited States, Germany, Japan
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedLymphoproliferative DisorderCanada, United States, Australia, New Zealand
-
Deepa JagadeeshTerminatedPost-transplant Lymphoproliferative DisorderUnited States
Clinical Trials on therapeutic allogeneic lymphocytes
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Hodgkin Lymphoma | Recurrent Adult Acute Myeloid Leukemia | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Non-Hodgkin Lymphoma | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Recurrent Plasma Cell MyelomaUnited States, Germany, Italy
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)TerminatedKidney CancerUnited States
-
Asan Medical CenterCompleted
-
Robert LowskyNational Cancer Institute (NCI)CompletedRecurrent Adult Acute Myeloid Leukemia | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Recurrent Adult Immunoblastic Large... and other conditionsUnited States
-
University of ChicagoNational Cancer Institute (NCI)CompletedRecurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent... and other conditionsUnited States
-
Eastern Cooperative Oncology GroupNational Cancer Institute (NCI)CompletedMultiple Myeloma and Plasma Cell NeoplasmUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)No longer availableInfection | Precancerous/Nonmalignant ConditionUnited States
-
University of Medicine and Dentistry of New JerseyNational Cancer Institute (NCI)Completed
-
Milton S. Hershey Medical CenterNational Cancer Institute (NCI)Unknown
-
Sumithira VasuRecruitingCytomegalovirus | Adenovirus | Donor | Allogeneic Hematopoietic Stem Cell Transplantation Recipient | Solid Organ Transplantation RecipientUnited States